One Biosciences Establishes U.S. Operations in Albany
Overview
One Biosciences, based in Paris, France, will bring its proprietary technology to this first-of-its-kind hub in Albany to address the unmet clinical and scientific needs to characterize the tumor ecosystem. The company is developing technology to better understand each patient’s cancer, helping doctors around the world to match patients to the therapies most likely to help them.
In This Article
“Life science research and development is vital to creating the treatments that help people heal, survive and live longer. Through our targeted efforts, we are working to ensure that cutting edge companies like One Biosciences not only grow here, but that the next generation of medical breakthroughs happen in New York State.”
– Governor Kathy Hochul
“We are excited to accelerate support of our pharma, biotech, and academic collaborators through our AI-driven single-cell technologies, which will ultimately benefit physicians and their patients. The local Albany life sciences ecosystem gives us access to a community of like-minded researchers and physicians committed to leveraging technology to improve health and is an ideal location from where to serve the US globally.”
– Dr. Vincent Miller, One Biosciences Executive Chairman
The Big Picture
New York’s biotechnology and life sciences industry is an engine of economic growth. Research and development in biotech not only advances the public good, measured in groundbreaking advancements to cure disease, but also generates new high-paying jobs while opening pathways for entrepreneurs and start-ups.
In 2025, New York was home to 3,400 life science companies and approximately 70,000 life science jobs, representing increases of 46 percent and 21 percent, respectively, from a decade ago. Nationally, New York ranks second in National Institutes of Health funding with $3.55 billion in 2025, supporting 29,000 jobs and generating $8.25 billion in economic activity, and ranks third in bioscience-related venture capital investments, number of bioscience patents, and total drug development pipeline.
